Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce its latest results on its first-in-class blood test for esophageal adenocarcinoma, PromarkerEso, are being presented today at the 21st ISDE World Congress for Esophageal Diseases, in Brisbane, Australia, 18-20 September 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce it has been granted ISO 15189 certification for its Australian laboratory operations.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics and precision medicine, today announces a planned Board and Management transition.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce new results showing its first-in-class PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma (EAC) with high accuracy.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announces the Preliminary Final Report and Annual Report.
In this edition of The Ellis Martin Report and Money Talk Radio, we sit down with Shaun Bagai, Chief Executive Officer of RenovoRx, Inc. (NASDAQ:RNXT), a clinical-stage biopharmaceutical company pioneering a targeted, localized approach to treat hard-to-reach cancers.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics and precision medicine, is pleased to provide the following update on its business activities for the three months to 30 June 2025 and subsequent to the period end.
